NCT07009301

Brief Summary

Viper envenomation constitutes a medical emergency predominantly occurring in rural regions, where specific viper species are endemic, with their distribution influenced by climatic variations. The literature describes numerous complications associated with viper bites, including neurological disturbance, hematological abnormalities, and irreversible renal failure. We report the case of a 65-year-old female patient admitted to the intensive care unit for viper envenomation characterized by extensive local edema. Diagnostic investigations, including laboratory tests and imaging studies, revealed the presence of a bilateral pulmonary embolism. The patient was subsequently treated with antivenom therapy, followed by initiation of low molecular weight heparin. Despite the recognized high risk of viper envenomation described in the literature, the patient experienced an uncomplicated clinical course and was discharged in stable condition with no further complications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2025

Completed
15 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 25, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2025

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

May 29, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 6, 2025

Completed
Last Updated

June 6, 2025

Status Verified

May 1, 2025

Enrollment Period

15 days

First QC Date

May 29, 2025

Last Update Submit

May 29, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evolution of hematological blood test during the ICU stay

    From January 2025 to May 2025

Eligibility Criteria

Age18 Years - 100 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People aged above 18years, developing a pulmonary embolism after snake bites

You may qualify if:

  • Age above 18years old

You may not qualify if:

  • Not bitten by snakes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University hospital center Mohammed VI of Oujda

Oujda, Morocco

Location

MeSH Terms

Conditions

Pulmonary EmbolismSnake Bites

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesBites and StingsPoisoningChemically-Induced DisordersWounds and Injuries

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor Oujidi Younes

Study Record Dates

First Submitted

May 29, 2025

First Posted

June 6, 2025

Study Start

January 10, 2025

Primary Completion

January 25, 2025

Study Completion

May 20, 2025

Last Updated

June 6, 2025

Record last verified: 2025-05

Locations